Major depressive disorder is a common psychiatric disorder. The aim of the treatment is to improve daily functions with remissions in symptoms, and antidepressants are the first-line treatments for a major depressive episode (moderate-severe depressive episode). In this paper, the pharmacological properties, clinical efficacy and safety of extended-release trazodone (TzCOAD) are studied. Expert opinion: A single daily dose of TzCOAD may provide similar efficacy and increased tolerability to immediate-release trazodone (TzIR) and other antidepressants. [Anadolu Psikiyatri Derg 2019; 20(5.000): 453-459]